Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

VOLUNTARY ANNOUNCEMENT
EXPANDED COLLABORATION WITH ACEPODIA THROUGH OPTION-BASED EVALUATION FRAMEWORK FOR FIRST-IN-CLASS DUAL-PAYLOAD BISPECIFIC ANTIBODY-DRUG CONJUGATES PROGRAMS

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**" or "**Biocytogen**") to provide its shareholders and potential investors with information in relation to the latest development of the Company.

The board (the "**Board**") of directors of the Company is pleased to announce that recently, the Company have entered into an option and license agreement (the "**Agreement**") with Acepodia Inc. ("**Acepodia**") designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).

The Agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the Agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia's exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales.

The Agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection of leading bispecific antibody and dual-payload antibody-drug conjugates (ADC) candidates. Based on the preclinical research conducted to date, we believe that the combination of Biocytogen's RenLite® platform with Acepodia's Antibody-Dual-Drugs Conjugation (AD2C) technology offers a compelling approach for the development of next-generation dual-payload bispecific BsAD2Cs.

The expanded partnership is intended to leverage complementary platform strengths to advance next-generation ADC designs with the potential to improve upon certain limitations observed in conventional ADC programs. The joint team is progressing towards candidate evaluation milestones, with advancement decisions informed by ongoing research results and Acepodia's internal governance and option exercise criteria.

To the best knowledge and belief of the Directors, as of the date of this announcement, each of Acepodia and its ultimate beneficial owner(s) is independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The transactions contemplated under the Agreement do no constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, January 12, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive director, Dr. Ni Jian as executive director; Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive directors; and Ms. Li Yan as employee director.